Abstract

The use of neocytes has been developed as a system to reduce transfusion requirement and consequent iron overload. Neocyte concentrates prepared with the IBM 2991 Blood Processor have been transfused in 14 patients with Cooley's anemia (two groups of nine and five patients respectively). Analysis of the clinical advantages of neocytes has demonstrated that (1) the reduction of the blood requirement was about 10%; (2) the cost of a neocyte unit is considerable compared with the standard blood unit; and (3) the risk of alloimmunization and blood-dependent infectious disease is increased, in proportion to the large numbers of blood donors.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.